351324-70-4 Usage
Description
Tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate is an organic compound that serves as a valuable intermediate in the synthesis of various organic compounds. It is characterized by its unique molecular structure, which includes a quinoline ring and a carboxylate group, making it a versatile building block for further chemical reactions and modifications.
Uses
Used in Pharmaceutical Industry:
Tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure allows for the creation of diverse molecules with potential therapeutic applications, such as the development of novel drugs for the treatment of various diseases.
Used in Chemical Research:
In the field of chemical research, tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate is used as a reactant for the synthesis of complex organic molecules. Its reactivity and structural features make it a valuable tool for exploring new chemical reactions and understanding the underlying mechanisms involved in these processes.
Used in Material Science:
Tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate can also be utilized in the development of new materials with specific properties. Its incorporation into the molecular structure of these materials can lead to the creation of materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 351324-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,3,2 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 351324-70:
(8*3)+(7*5)+(6*1)+(5*3)+(4*2)+(3*4)+(2*7)+(1*0)=114
114 % 10 = 4
So 351324-70-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H20N2O2/c1-14(2,3)18-13(17)16-8-4-5-10-6-7-11(15)9-12(10)16/h6-7,9H,4-5,8,15H2,1-3H3
351324-70-4Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 0618, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
Non-peptidic NPY Y2 receptor inhibitors
-
Page/Page column 13, (2010/02/11)
The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.